Effect of acute and sub chronic use of Bacopa monnieri on dopamine and serotonin turnover in mice whole brain

African journal of pharmacy and pharmacology (Impact Factor: 0.84). 10/2012; 6(39)(39):2767-2774.

ABSTRACT Bacopa monnieri (BM) is a perennial herb, with a historic nootropic image and utility in ayurvedic system of medicine, for the management of various central nervous system disorders like, epilepsy, depression, memory deficit, etc. We investigated the effects of acute and sub chronic (one week) treatment of BM methanolic extract (Mt-ext BM) on dopamine (DA) and serotonin (5-HT) turn over in mice whole brain. Mt-ext BM was screened on high performance liquid chromatography (HPLC) with ultraviolet (UV) detection for the quantification of BM major bioactive compound, Bacoside A, mainly comprising of Bacopasaponin C, Bacoside A3, and Bacopaside ll. For acute study, mice groups were administered single dose of 10, 20 or 30 mg/kg of Mt-ext BM orally, while in sub chronic study separate groups received single daily dose of 10, 20 or 30 mg/kg of Mt-ext BM orally for one week. Animals were killed 1 h after the dose by decapitation, and whole brains were excised and analyzed on HPLC coupled with electrochemical detector for changes in DA, 5-HT, dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and 5 hydroxyindolacetic acid (5HIAA). Our results show that both acute and sub chronic oral administration of Mt-ext BM have no significant effect on DA and 5-HT turn over. The neurotransmitters data reflects safety of the BM in acute and sub chronic uses from DA and 5-HT modulation and subsequent pre disposition to neuropsychiatric problems. Although more studies are warranted to explore BM role in DA and 5-HT interplay in specified brain regions. Key words: Bacoside A, Bacopa monnieri, high performance liquid chromatography (HPLC), dopamine (DA), serotonin (5-HT).

1 Follower
  • Federation proceedings 10/1980; 39(11):2923-30.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The fundamental principle that unites addictive drugs appears to be that each enhances synaptic dopamine by means that dissociate it from normal behavioral control, so that they act to reinforce their own acquisition. This occurs via the modulation of synaptic mechanisms that can be involved in learning, including enhanced excitation or disinhibition of dopamine neuron activity, blockade of dopamine reuptake, and altering the state of the presynaptic terminal to enhance evoked over basal transmission. Amphetamines offer an exception to such modulation in that they combine multiple effects to produce nonexocytic stimulation-independent release of neurotransmitter via reverse transport independent from normal presynaptic function. Questions about the molecular actions of addictive drugs, prominently including the actions of alcohol and solvents, remain unresolved, but their ability to co-opt normal presynaptic functions helps to explain why treatment for addiction has been challenging.
    Neuron 02/2011; 69(4):628-49. DOI:10.1016/j.neuron.2011.02.010 · 15.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: What roles do mesolimbic and neostriatal dopamine systems play in reward? Do they mediate the hedonic impact of rewarding stimuli? Do they mediate hedonic reward learning and associative prediction? Our review of the literature, together with results of a new study of residual reward capacity after dopamine depletion, indicates the answer to both questions is `no'. Rather, dopamine systems may mediate the incentive salience of rewards, modulating their motivational value in a manner separable from hedonia and reward learning. In a study of the consequences of dopamine loss, rats were depleted of dopamine in the nucleus accumbens and neostriatum by up to 99% using 6-hydroxydopamine. In a series of experiments, we applied the `taste reactivity' measure of affective reactions (gapes, etc.) to assess the capacity of dopamine-depleted rats for: 1) normal affect (hedonic and aversive reactions), 2) modulation of hedonic affect by associative learning (taste aversion conditioning), and 3) hedonic enhancement of affect by non-dopaminergic pharmacological manipulation of palatability (benzodiazepine administration). We found normal hedonic reaction patterns to sucrose vs. quinine, normal learning of new hedonic stimulus values (a change in palatability based on predictive relations), and normal pharmacological hedonic enhancement of palatability. We discuss these results in the context of hypotheses and data concerning the role of dopamine in reward. We review neurochemical, electrophysiological, and other behavioral evidence. We conclude that dopamine systems are not needed either to mediate the hedonic pleasure of reinforcers or to mediate predictive associations involved in hedonic reward learning. We conclude instead that dopamine may be more important to incentive salience attributions to the neural representations of reward-related stimuli. Incentive salience, we suggest, is a distinct component of motivation and reward. In other words, dopamine systems are necessary for `wanting' incentives, but not for `liking' them or for learning new `likes' and `dislikes'.
    Brain Research Reviews 01/1999; 28(3-28):309-369. DOI:10.1016/S0165-0173(98)00019-8 · 5.93 Impact Factor